Skip to main content

Table 1 Demographic and clinical patient characteristics

From: Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs)

Characteristics Values
Age 59.7 ± 10.8
Gender, female 100 (67)
Disease duration (year) 12.2 ± 9.1
Biological treatment duration >2 years 120 (80)
Patient measures
 Function (0–10) 2.6 ± 1.8 (total; n = 150 patients)
4.2 ± 1.8 (DAS28-ESR >5.1; n = 22)
3.2 ± 1.5 (DAS28-ESR ≥3.2 to ≤5.1; n = 50)
2.4 ± 1.7 (DAS28-ESR ≥2.6 to <3.2; n = 31)
1.4 ± 1.4 (DAS28-ESR <2.6; n = 47)
 Pain (0–10) 4.4 ± 2.5 (total; n = 150 patients)
6.6 ± 1.4 (DAS28-ESR >5.1; n = 22)
4.8 ± 2.2 (DAS28-ESR ≥3.2 to ≤5.1; n = 50)
4.1 ± 2.3 (DAS28-ESR ≥2.6 to <3.2; n = 31)
3.1 ± 2.4 (DAS28-ESR <2.6; n = 47)
 Patient global estimate VAS (0–10) 4.7 ± 2.5 (total; n = 150 patients)
6.8 ± 1.2 (DAS28-ESR >5.1; n = 22)
5.2 ± 2.3 (DAS28-ESR ≥3.2 to ≤5.1; n = 50)
4.2 ± 2.3 (DAS28-ESR ≥2.6 to <3.2; n = 31)
3.6 ± 2.6 (DAS28-ESR <2.6; n = 47)
Disease activity indices
 DAS28-ESR 3.4 ± 1.4
 RAPID3 11.7 ± 6.2
Medications
 Etanercept (Enbrel) 61 (40.7)
 Adalimumab (Humira) 53 (35.3)
 Tocilizumab (Roactemra) 21 (14)
 Abatacept (Orencia) 8 (5.3)
 Infliximab (Remicade) 6 (4)
 Certolizumab (Cimzia) 1 (0.7)
 Methotrexate weekly (5–25 mg) combination therapy 34 (23)
  1. Data expressed as mean ± SD for continuous variables and n (%) for categorical variables
  2. DAS28 disease activity index, ESR erythrocyte sedimentation rate, RAPID3 routine assessment of patient index data 3